Clinical Trials · NCT03671330

Efficacy and Safety of Ribociclib in Pre- and Postmenopausal Chinese Women With HR Positive, HER2-negative, Advanced Breast Cancer.

Name: Efficacy and Safety of Ribociclib in Pre- and Postmenopausal Chinese Women With HR Positive, HER2-negative, Advanced Breast Cancer.
Creator: Peptide Science Daily
License: https://clinicaltrials.gov/about-site/terms-conditions

CompletedPhase 2Gonadorelin

Phase: Phase 2
Recruitment status: Completed
Sponsor: Novartis Pharmaceuticals
Enrollment: 327
Start date: Aug 2018
Locations: 24 sites, China
Primary endpoint: Pre and Postmenopausal Cohorts: Progressive Free Survival (PFS) Based on Local Assessment by RECIST 1.1 Guideline

View Gonadorelin compound reference